249 related articles for article (PubMed ID: 25792453)
1. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Muylle K; Flamen P; Vugts DJ; Guiot T; Ghanem G; Meuleman N; Bourgeois P; Vanderlinden B; van Dongen GA; Everaert H; Vaes M; Bron D
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1304-14. PubMed ID: 25792453
[TBL] [Abstract][Full Text] [Related]
2. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
3. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
[TBL] [Abstract][Full Text] [Related]
4. Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.
Tran L; Huitema AD; Vogel WV; Beijnen JH; Baars JW
J Oncol Pharm Pract; 2012 Dec; 18(4):417-20. PubMed ID: 22228555
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.
Sjögreen-Gleisner K; Dewaraja YK; Chiesa C; Tennvall J; Lindén O; Strand SE; Ljungberg M
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):126-54. PubMed ID: 21386787
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.
Forrer F; Oechslin-Oberholzer C; Campana B; Herrmann R; Maecke HR; Mueller-Brand J; Lohri A
J Nucl Med; 2013 Jul; 54(7):1045-52. PubMed ID: 23572496
[TBL] [Abstract][Full Text] [Related]
9. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
10. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma.
Natarajan A; Hackel BJ; Gambhir SS
Clin Cancer Res; 2013 Dec; 19(24):6820-9. PubMed ID: 24097872
[TBL] [Abstract][Full Text] [Related]
11. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
12. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Jauw YW; Zijlstra JM; de Jong D; Vugts DJ; Zweegman S; Hoekstra OS; van Dongen GA; Huisman MC
PLoS One; 2017; 12(1):e0169828. PubMed ID: 28060891
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and Dosimetry of Indigenously Produced
Adnan A; Deep K; Kameswaran M; Nikam D; Shanmukaih C; Dash A; Banerjee S; Basu S
J Nucl Med Technol; 2019 Dec; 47(4):292-299. PubMed ID: 30413603
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
15. Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics.
Antonescu C; Bischof Delaloye A; Kosinski M; Monnin P; Schaffland AO; Ketterer N; Grannavel C; Kovacsovics T; Verdun FR; Buchegger F
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):943-51. PubMed ID: 15824926
[TBL] [Abstract][Full Text] [Related]
16. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
17. [Radioimmunotherapy for B-cell lymphoma].
Tobinai K
Rinsho Ketsueki; 2006 Jun; 47(6):463-70. PubMed ID: 16862974
[No Abstract] [Full Text] [Related]
18. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
[TBL] [Abstract][Full Text] [Related]
19. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
